NanoVibronix Adds Additional Product to Federal Supply Schedule
April 25 2022 - 8:30AM
Business Wire
PainShield Plus and PainShield Monthly Kits
Join UroShield and PainShield MD with Access to VA Market
NanoVibronix, Inc., (NASDAQ: NAOV), a medical device
company that produces the UroShield®, PainShield® and WoundShield®
Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic
Devices, today announced that its PainShield Plus and PainShield
Monthly Kit products have been added to the Federal Supply Schedule
(FSS) through a service disabled veteran organization. With these
recent additions, NanoVibronix is able to make three of its leading
products available to veterans, increasing access to non-opioid
pain therapy and delivering positive patient outcomes. The two new
products join the Company’s UroShield urology therapy device and
original PainShield MD product on the FSS.
PainShield Plus utilizes ultrasound therapy for the treatment of
pain and various soft tissue injuries either directly over joints
or orthopedic hardware and without the need for messy ultrasound
gels. The device is an effective solution for avoiding opioid
treatments and supports social distancing by equipping patients to
receive therapy independently in the comfort and safety of their
own homes. Patient benefits include ease of application and use,
faster recovery time, high compliance, and increased safety and
efficacy over existing devices that rely on higher-frequency
ultrasound.
“Our new additions to the FSS are an important achievement for
NanoVibronix, further broadening our portfolio of products and the
treatment options available to Veterans,” stated Brian Murphy, CEO
of NanoVibronix. “We believe that our products deliver superior
therapeutic value and are safe, easy-to-use, and highly effective
in treating soft tissue pain. We are strongly encouraged by the
early adoption that our products have received at the VA and look
forward to further educating this important market on their
long-term benefits.”
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company
headquartered in Elmsford, New York, with research and development
in Nesher, Israel, focused on developing medical devices utilizing
its patented low intensity surface acoustic wave (SAW) technology.
The proprietary technology allows for the creation of low-frequency
ultrasound waves that can be utilized for a variety of medical
applications, including for disruption of biofilms and bacterial
colonization, as well as for pain relief. The devices can be
administered at home without the assistance of medical
professionals. The Company’s primary products include PainShield®,
UroShield® and WoundShield®, all of which are portable devices
suitable for administration at home without assistance of medical
professionals. Additional information about NanoVibronix is
available at: www.nanovibronix.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified; consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and
uncertainties associated with: (i) the geographic, social and
economic impact of COVID-19 on the Company’s ability to conduct its
business and raise capital in the future when needed, (ii) market
acceptance of our existing and new products or lengthy product
delays in key markets; (iii) negative or unreliable clinical trial
results; (iv) inability to secure regulatory approvals for the sale
of our products; (v) intense competition in the medical device
industry from much larger, multinational companies,; (vi) product
liability claims; (vii) product malfunctions; (viii) our limited
manufacturing capabilities and reliance on subcontractor
assistance; (ix) insufficient or inadequate reimbursements by
governmental and/or other third party payers for our products; (x)
our ability to successfully obtain and maintain intellectual
property protection covering our products; (xi) legislative or
regulatory reform impacting the healthcare system in the U.S. or in
foreign jurisdictions; (xii) our reliance on single suppliers for
certain product components, (xiii) the need to raise additional
capital to meet our future business requirements and obligations,
given the fact that such capital may not be available, or may be
costly, dilutive or difficult to obtain; (xiv) our conducting
business in foreign jurisdictions exposing us to additional
challenges, such as, e.g., foreign currency exchange rate
fluctuations, logistical and communications challenges, the burden
and cost of compliance with foreign laws, and political and/or
economic instabilities in specific jurisdictions; and (xv) market
and other conditions. More detailed information about the Company
and the risk factors that may affect the realization of forward
looking statements is set forth in the Company’s filings with the
Securities and Exchange Commission (SEC), including the Company’s
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents
free of charge on the SEC’s web site at: http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events, or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220425005553/en/
Investor Contacts:
NanoVibronix, Inc. bmurphy@nanovibronix.com (630) 338-5022
Or:
Brett Maas, Managing Principal, Hayden IR, LLC
brett@haydenir.com (646) 536-7331
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Apr 2023 to Apr 2024